Fundraising Fox
/Companies
Sign in

Pairidex, Inc.

St. Louis, US · Founded 2023 · Delaware corporation · 2 known investors

Find your way into Pairidex, Inc.

Each arrow is one introduction. Sign up to fill in the first one.

153 people can intro you to Paul

Ask David Adair to introduce you to Paul Kortschak

You →David · together at NX PRENATAL INC. →Paul

Sign up to find every way you can get introduced to Pairidex, Inc.

  • Your email: who you already know at Pairidex, Inc., and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Pairidex, Inc. team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Pairidex offers FusionMRD, a personalized digital droplet PCR (ddPCR) assay that detects and quantifies oncogenic gene fusions from a standard peripheral blood sample to monitor treatment response and minimal residual disease in gene fusion-driven blood cancers such as leukemia. It is sold as a commercial service for oncologists and clinical researchers to support treatment decisions and shorten clinical trial timelines.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

Pairidex, Inc. was founded in 2023 by Grant Challen.

GCGrant Challen
Grant ChallenCo-Founder & Scientific Advisor
AMAllyson Mayer
Allyson MayerInterim COOPrincipal at BioGenerator Ventures
AYAndrew Young
Andrew YoungFounder & CSO
PKPaul Kortschak
Paul KortschakCEOPaul Kortschak is CEO of Pairidex, which develops FusionMRD, a blood-based digital droplet PCR assay for monitoring minimal residual disease in gene fusion-driven leukemias. He has over 25 years of experience in molecular and clinical diagnostics, with prior roles at Karius, QIAGEN, Roche Molecular Systems, Bio-Rad, and in healthcare IT across the U.S., Asia, and Europe.

Board

TD
Todd DruleyBoard director
CW
Crystal WinkelerBoard directorManaging Director at BioGenerator Ventures

Investors · 2

iSelect Fundlisted by iSelect FundSt. Louis · $250K – $2M

Reported raises · per SEC filings

Form D private placements

$1.1M disclosed across 1 round · 2024

▶$1.1MraisedFeb 2025 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Todd DruleyDirector
  • Crystal WinkelerDirector
  • Allyson MayerExecutive Officer
  • Andrew YoungExecutive Officer, Director
Offering amount
$1.1M
Amount sold
$1.1M
Minimum investment
$25K
First sale
May 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

PredxbioPredxBio develops tissue analysis software that uses spatial multi-omics data to identify biomarkers and inform drug development decisions. The platform helps pharmaceutical and biotech companies move from exploratory tissue analysis to clinical development with explainable insights about cell states, microenvironments, and therapeutic response patterns.

Companies working in the same space as Pairidex, Inc..

Frequently asked questions

What does Pairidex, Inc. do?
Pairidex offers FusionMRD, a personalized digital droplet PCR (ddPCR) assay that detects and quantifies oncogenic gene fusions from a standard peripheral blood sample to monitor treatment response and minimal residual disease in gene fusion-driven blood cancers such as leukemia. It is sold as a commercial service for oncologists and clinical researchers to support treatment decisions and shorten clinical trial timelines.
Who founded Pairidex, Inc.?
Pairidex, Inc. was founded by Grant Challen in 2023.
Who are Pairidex, Inc.'s investors?
Pairidex, Inc.'s investors include BioGenerator Ventures, iSelect Fund.
How much funding has Pairidex, Inc. raised?
Pairidex, Inc. has disclosed $1.1M raised across 1 round.
Where is Pairidex, Inc. headquartered?
Pairidex, Inc. is headquartered in St. Louis, US.